Compare VTIX & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTIX | CYPH |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.9M | 73.3M |
| IPO Year | 2025 | 2019 |
| Metric | VTIX | CYPH |
|---|---|---|
| Price | $1.33 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 773.3K | ★ 1.8M |
| Earning Date | 08-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 58.99 | ★ 103.87 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,252,643.00 | $1,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.44 | N/A |
| 52 Week Low | $1.42 | $0.49 |
| 52 Week High | $9.00 | $3.70 |
| Indicator | VTIX | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 28.35 | 79.45 |
| Support Level | N/A | $1.10 |
| Resistance Level | $2.03 | $1.32 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 6.67 | 82.88 |
Virtuix Holdings Inc pioneers movement in AI-generated worlds, both imaginary and real. The company is the creator of Omni, a brand of omni-directional treadmills that enable users to walk and run in 360 degrees inside virtual reality (VR) games, digital twins, and other applications. Its technology operates at the intersection of gaming, fitness, and enterprise VR. Its products include Omni Pro, Omni Arena, and Omni One. Its business integrates a consumer and enterprise VR hardware platform anchored by its flagship Omni One product with a defense-oriented simulation system, Virtual Terrain Walk (VTW), targeting next-generation immersive mission planning.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.